

DONCASTER & BASSETLAW AREA PRESCRIBING COMMITTEE (APC)

Action Notes and Log

Thursday 28th October 2021 12 Noon start

Meeting held over Microsoft Teams

Present:	Dr David Crichton Mr Alex Molyneux Mrs Charlotte McMurray Mr Rob Wise Dr Rachel Hubbard Dr Rumit Shah Miss Ning Wong Mrs Karen Jennison	Chair, APC Chair DCCG Head of Medicines Management DCCG Deputy Head of Medicines Management DCCG Head of Medicines Management, Deputy APC Chair BCCG Doncaster GP Local Medical Committee Representative Locality Lead Pharmacist Senior Medicines Management Technician DCCG (Secretary)
In attendance:	Miss Ning Wong Mrs Helen Cunningham	Locality Lead Pharmacist Practice Support Technician
Minutes only:	Dr Rupert Suckling & Dr Victor Joseph	DMBC Representatives

Agenda Ref	Subject / Action Required	Action Required By	Timescale	Status of Action (RAG) and Date
10/21/1	<p>Apologies for Absence: Lee Wilson, Jennifer Cox, Lucy Peart and Stephen Davies.</p> <p>Ning Wong in attendance as Locality Lead Pharmacist representation and Helen Cunningham in attendance as part of her MMT induction program.</p> <p>Rumit Shah, Alex Molyneux and Charlotte McMurray advised the Chair that they needed to leave the meeting at approximately 13:00. Some agenda items were brought forward to ensure decisions were made when the committee was quorate.</p>			
10/21/2	Declarations of Interest: None			
10/21/2.1	Fire Alarm Procedure: N/A Meeting online			
10/21/2.2	Notification of Any Other Business: None			
10/21/3	<p>Notes of the Meeting Held On: Thursday 30th September 2021 were agreed as a true and accurate record with one amendment 9/21/4- Rob Wise noted that this item referred to Doncaster APC and pointed out that it should be Doncaster and Bassetlaw APC. It was agreed to remove the word 'Doncaster'.</p> <p>The sentence will then read <i>'RW updated the group on feedback from the Bassetlaw GP prescribing leads meeting, who were commenting on the April APC Action Log regarding Vitamin D guidance around pregnancy and queried if the APC had considered including blood test monitoring into the current guidelines'</i></p>			
10/21/4	Matters Arising not on the agenda:			
10/21/4.1	Matters Arising			

	To note that the APC have approved the SCP for use at Bassetlaw CCG.			
10/21/10	<p>Drugs for Review:</p> <p>Bromocriptine - Lactation suppression after intrapartum loss or neonatal death was agreed to switch from Green-G to Grey</p> <p>Conjugated Oestrogens/ Bazedoxifene (DUAVIVE) - Oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate was agreed to remain as Green-G (Non-formulary)</p> <p>Naloxone/Oxycodone prolonged release (Targinact) - Restless legs syndrome (idiopathic) was agreed to remain Grey</p> <p>Panitumumab (Vectibix) - Metastatic colon cancer as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens was agreed to remain Grey</p> <p>Regorafenib (Stivarga) - Cancer - Colorectal (metastatic) in adults who have been previously treated with, or are not considered candidates for, available therapies was agreed to be switched from Grey to Red</p> <p>Inclisiran (Leqvio) – Secondary prevention in Adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia</p> <p>Ning Wong shared a request for a new TLS entry for Inclisiran. There was a lengthy debate on how to move forward with this matter, NHS England have issued a letter to CCG' s to give this drug a Green TLS entry. The committee questioned the 30-day deadline, which is not in line with the usual decision-making process for new drugs.</p> <p>A proposed pathway for lipid management is in the process of being developed and it was felt that it would require a detailed monitoring flowchart to assist in the correct initiation of this drug. It was thought that most prescribers would prefer to have guidance available before initiating this drug.</p> <p>An initial search has been undertaken to identify eligible patients however it was anticipated that the patient count would be small, given the several factors to take into consideration for eligibility. Ning Wong is currently liaising with her peers across SYB so that there is a standard approach across the ICS.</p>			

	<p>The committee decided to follow due process and this will be taken this to the next MMG meeting, with a view to bringing a decision back to the APC at the end of November.</p> <p>It was suggested that Ning Wong and Rachel Hubbard should liaise with Nabeel Alsindi in the Primary Care team to have some input into the pathway currently being developed.</p> <p>David Crichton agreed to share this with the CCG Senior Management Team meeting to keep them informed of the discussions today. Rob Wise agreed to do likewise for Bassetlaw.</p>	<p>NHSD-NW/RH</p> <p>NHSD-DC & NHSB-RW</p>		
10/21/11	<p>Officers' Actions and returning drugs</p> <p>All officers' actions were approved with the following points being made: -</p> <ul style="list-style-type: none"> • Choriogonadotropin Alfa and Chorionic Gonadotrophin could be merged as one entry • Items that lose their NICE status and no longer have a place in therapy should not be removed from the TLS but classified as Grey Non-Formulary to ensure prescribers can obtain a TLS status. <p>The returning drugs were received by the committee for information</p>	<p>NHSD-JC/KJ</p>		
10/21/12	<p>Drugs for Consideration:</p> <p>Ropeginterferon alfa-2b (Besremi) - Polycythaemia vera without symptomatic splenomegaly was agreed to be classified as Red</p> <p>Tralokinumab (Adtralza) - Atopic dermatitis in adult patients who are candidates for systemic therapy was agreed to be classified as Red</p> <p>Ponesimod (Ponvory) - Relapsing forms of multiple sclerosis (RMS) was agreed to be classified as Red</p> <p>ACARIZAX 12 SQ-HDM - House dust mite sensitisation</p> <p>And ITULAZAX 12 SQ-Bet - Allergic rhinitis and/or conjunctivitis induced by pollen from the birch homologous group. It was agreed to consult Immunology at Sheffield to request guidance on classification</p> <p>These 2 items to be taken to the next MMG for discussion APC recommends RED 1,2 for both.</p>	<p>NHSD-CM</p>		

	<p>Tirbanibulin (Klisyri) - Non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults to be taken to the next MMG for discussion APC recommends to be classified as Amber-G</p> <p>Stiripentol (Diacomit) - Severe myoclonic epilepsy in infancy (SMEI, Dravet's syndrome) was deferred to the next APC meeting in November.</p>			
10/21/13	New Business			
10/21/13.1	<p>APG Form bath – SCH Response to the STOP list – Bath and Shower Emollients</p> <p>Charlotte McMurray informed the committee that Sheffield Children’s Dermatology consultants have requested that a small number of children may still require emollient bath and shower products on prescription in Sheffield. The committee discussed the document, and it was agreed that the evidence did not support the prescribing of emollient bath and shower products, and this is going against the message of self-care.</p> <p>The committee decided not to adopt the document, although accepted that there may be exceptionality in a small number of patients.</p> <p>There was ongoing support for general moisturisers to be used as soap substitute as the alternative.</p>			
10/21/13.2	<p>Moderna COVID-19 vaccine Patient Group Directions</p> <p>The PDG was brought to the APC for approval. It was noted that Doncaster is currently using the Pfizer vaccine but acknowledged that the Moderna Vaccine could be used in some circumstances as an alternative.</p> <p>The PGD was approved.</p>			
10/21/13.3	<p>Ocular Lubricant Guidance</p> <p>The Ocular Lubricant Guidance is in final draft and was discussed at the meeting. It was suggested that the term ‘tired eyes’ be removed from the guidance as this is not a clinical term.</p> <p>There was also a suggested spelling correction, Rob Wise will make the agreed amendments and will forward to Karen Jennison to update the MMT website.</p>			
10/21/14	<p>DBTHFT D&TC Update:</p> <p>The Committee have not received up to date minutes</p>			

10/21/15	Formulary Liaison Group Update The Committee have not received up to date minutes			
10/21/16	DCCG Medicines Management Group The Committee received minutes from the meeting held September 2021			
10/21/17	RDASH FT Medicines Management Committee update The Committee have not received up to date minutes			
10/21/18	Barnsley Area Prescribing Committee Update The Committee have not received up to date minutes			
10/21/19	Rotherham Medicines Optimisation Group Update The Committee have not received any up-to-date minutes			
10/21/20	Sheffield Area Prescribing Committee Update The Committee received minutes from the meeting held July 2021 It was noted that the Shared Care Protocol for Topical testosterone replacement therapy in post-menopausal women was discussed, and the committee agreed that this should be brought to the next APC to formally discuss. Alex Molyneux will discuss with Charlotte McMurray as Dr Sitwell is keen to extend this across the ICS.	NHSD-AM/CM		
10/21/21	Nottingham Area Prescribing Committee Update The Committee have not received any up-to-date minutes			
10/21/22	SY& B ICS Medicines Optimisation Work-stream Steering Group The Committee received the August 2021 action and decision log			
10/21/23	Northern Regional Medicines Optimisation Committee The Committee have not received any up-to-date minutes			

10/21/24	Any Other Business: None			
10/21/25	Date and Time of Next Meeting: 12 noon prompt Thursday 25th November 2021 Meeting via Microsoft Teams			

KEY

Completed / Closed	To Action
In Progress	To be actioned but date not yet due